Pernod Ricard Q1 sales fall less than expected as India offsets U.S., China slump

Pernod Ricard’s first-quarter organic sales declined 0.9%, a smaller fall than the 1.7% consensus decline, as volumes rose 6% and India sales grew 19%. Those gains were offset by sales declines of 10% in the U.S. and 25% in China; reported sales fell 6.3% to €2.23 billion. The company kept its full-year outlook for organic sales to be broadly stable and, for fiscal 2027–2029, targets average growth close to the lower end of its 3%–6% range.

Analysis

The beat has low quality as a read-through to durable demand: India’s reported strength includes IPO preparation-related pipe-fill and a favorable excise-policy comparison, both of which can pull sales forward. A standalone India listing could crystallize value, but until scope, proceeds use, and post-listing control are clear, it is not a reliable near-term valuation catalyst for Pernod Ricard (RI). The key distinction is sell-in versus consumption: US and China inventory correction can depress shipments even as underlying demand stabilizes, but China depletion growth needs confirmation across channels before assuming restocking.

Near term (days), the better signal is the maintained cautious outlook rather than the quarterly beat; avoid extrapolating India’s growth into the group. Over 1–3 months, watch China depletions versus shipments, US distributor inventories, and whether India growth persists after the IPO-related fill. Over 6–18 months, the efficiency program could support margins, but weak US/China volumes and mix may absorb savings; the lower-end growth ambition is not evidence of a near-term reacceleration.

Contrarian point: a large part of the China shipment decline may be channel correction, so stabilization in sell-through could produce a sharper shipment recovery than current reported sales suggest. Conversely, if channel normalization fails, India’s one-off support will make the underlying weakness more visible. No high-conviction directional trade until channel data and IPO terms clarify the earnings and valuation bridge.

Key Decisions for Investors

• Keep RI at neutral/underweight rather than buying the quarterly beat; reassess after the next channel update. The thesis improves if China depletions remain positive and shipment declines narrow without renewed inventory build; it is falsified by renewed depletion weakness or a further deterioration in full-year guidance.
• Treat a proposed India IPO as an event watch, not a standalone buy catalyst. Verify the business perimeter, listing timetable, ownership retained, and intended use of proceeds before assigning value; a delay or terms that leave limited value with RI would weaken the catalyst.
• For a relative-value expression, consider a modest short RI versus a diversified consumer-staples exposure only if US/China sell-in remains weak and guidance is cut; define the exit around evidence of channel normalization or a guidance stabilization. Avoid sizing as a structural short given the possibility of China restocking and operational-efficiency delivery.